Skip to main content
Premium Trial:

Request an Annual Quote

RXi Begins Second Phase I Trial of Anti-Scarring Drug

Premium

RXi Pharmaceuticals this week announced that it has started a second double-blind phase I study of its RNAi-based anti-scarring compound RXI-109.

Three cohorts of three patients each will be enrolled to receive three intradermal injections of the drug over two weeks. Dose levels range from 2.5 mg to 7.5 mg per injection, and subjects will receive injections of RXI-109 and its delivery vehicle without the RNAi payload at small incisions on separate areas of their abdomen. 

Last month, RXi released final results from a single-dose phase I trial of the drug, showing that it was well tolerated in healthy volunteers scheduled to undergo abdominoplasty (GSN 11/15/2012).

“If we can continue at this pace, and assuming no unexpected hurdles, [we] should be able to move into [our] first phase II studies with RXI-109 in the second half of 2013,” RXi President and CEO Geert Cauwenbergh said in a statement.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.